drugset / Trial / NCT00452218
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of sorafenib in patients with PAH already on existing therapy with a prostacyclin \[epoprostenol (Flolan)\], treprostinil (Remodulin), or iloprost alone, or with or without sildenafil (Viagra/Revatio).
Timeline
- Start
- 2007-03
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | — |